"Mast-Cell Sarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A unifocal malignant tumor that consists of atypical pathological MAST CELLS without systemic involvement. It causes local destructive growth in organs other than in skin or bone marrow.
| Descriptor ID |
D012515
|
| MeSH Number(s) |
C04.557.450.565.465.124
|
| Concept/Terms |
Mast-Cell Sarcoma- Mast-Cell Sarcoma
- Mast Cell Sarcoma
- Mastocytoma, Malignant
- Malignant Mastocytoma
- Malignant Mastocytomas
- Mastocytomas, Malignant
- Sarcoma, Mast-Cell
- Mast-Cell Sarcomas
- Sarcoma, Mast Cell
- Sarcomas, Mast-Cell
|
Below are MeSH descriptors whose meaning is more general than "Mast-Cell Sarcoma".
Below are MeSH descriptors whose meaning is more specific than "Mast-Cell Sarcoma".
This graph shows the total number of publications written about "Mast-Cell Sarcoma" by people in this website by year, and whether "Mast-Cell Sarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 2 | 5 |
| 1997 | 2 | 0 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 2 | 3 |
| 2003 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mast-Cell Sarcoma" by people in Profiles.
-
Promiscuity of MHC class Ib-restricted T cell responses. J Immunol. 2003 Dec 01; 171(11):5948-55.
-
CD28 is not required for c-Jun N-terminal kinase activation in T cells. J Immunol. 2001 Sep 15; 167(6):3123-8.
-
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001 Jul; 25(7):603-25.
-
Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int Immunol. 2001 May; 13(5):625-32.
-
Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J Immunol. 2000 Dec 01; 165(11):6024-8.
-
Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol. 1999 Oct 15; 163(8):4109-13.
-
B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells. J Immunol. 1998 Nov 15; 161(10):5268-75.
-
Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells. Int Immunol. 1997 Sep; 9(9):1259-69.
-
The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int J Cancer. 1997 Jan 27; 70(3):349-56.
-
Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int J Cancer. 1996 Jul 17; 67(2):303-10.